source
- Industry groups seek clarifications in FDA’s ANDA and 505(b)(2) guidanceBrand-name and generic pharmaceutical groups are recommending clarifications to the US Food and Drug Administration’s (FDA) guidance on when to submit an abbreviated new drug application (ANDA) or…raps · 1d ago↗ source
- AI for conformity assessments: Experts highlight use cases, pitfallsBARCELONA – A panel of experts at the RAPS AI in Regulatory Conference discussed how artificial intelligence (AI) is being used by a wide range of stakeholders, including notified bodies and health…raps · 1d ago↗ source
- FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entryThe U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…